BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11:275-280. [PMID: 26321890 DOI: 10.1007/s11888-015-0285-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Baek JH, Baek DW, Kang BW, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. In Vivo. 2020;34:1993-1999. [PMID: 32606172 DOI: 10.21873/invivo.11997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Khushman M, Prodduturvar P, Mneimneh W, Zotto VD, Akbar S, Grimm L, Rider P, Hunter J, Alkharabsheh O, Patel GK, Fabregas JC, Singh AP. The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma. Oncotarget 2021;12:1490-8. [PMID: 34316329 DOI: 10.18632/oncotarget.28025] [Reference Citation Analysis]
3 Franke AJ, Parekh H, Starr JS, Tan SA, Iqbal A, George TJ. Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. Clinical Colorectal Cancer 2018;17:1-12. [DOI: 10.1016/j.clcc.2017.06.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
4 Oronsky B, Reid T, Larson C, Knox SJ. Locally advanced rectal cancer: The past, present, and future. Semin Oncol. 2020;47:85-92. [PMID: 32147127 DOI: 10.1053/j.seminoncol.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130 [PMID: 33643528 DOI: 10.4251/wjgo.v13.i2.119] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Fahmawi Y, Smith C, Grimm L, Khullar S, Rider P, Hunter J, Iliff G, Mneimneh W, Roveda K, Wang B, Prodduturvar P, Alkharabsheh O, McCormick B, Mizrahi M, Khushman M. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Clin Colorectal Cancer 2020;19:e281-7. [PMID: 32694005 DOI: 10.1016/j.clcc.2020.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Glynne-Jones R, Hall MR, Lopes A, Pearce S, Goh V, Bosompem S, Bridgewater J, Chau I, Wasan H, Moran B, Melcher L, West NP, Quirke P, Wong WL, Beare S, Hava N, Duggan M, Harrison M. BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). Heliyon. 2018;4:e00804. [PMID: 30258994 DOI: 10.1016/j.heliyon.2018.e00804] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Ucar G, Acikgoz Y, Ergun Y, Eren T, Dirikoc M, Esen SA, Yazıcı O, Uncu D, Ozdemir NY. Prognostic and Predictive Value of NAR Score in Gastric Cancer. J Gastrointest Cancer 2021;52:1054-60. [PMID: 33064272 DOI: 10.1007/s12029-020-00537-2] [Reference Citation Analysis]
9 Tuta M, Boc N, Brecelj E, Omejc M, Anderluh F, Ermenc AS, Peressutti AJ, Oblak I, Krebs B, Velenik V. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia. Radiol Oncol. 2019;53:465-472. [PMID: 31652124 DOI: 10.2478/raon-2019-0046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 van der Valk MJM, Vuijk FA, Putter H, van de Velde CJH, Beets GL, Hilling DE. Disqualification of Neoadjuvant Rectal Score Based on Data of 6596 Patients From the Netherlands Cancer Registry. Clin Colorectal Cancer 2019;18:e231-6. [PMID: 30772135 DOI: 10.1016/j.clcc.2019.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
11 Zhou P, Goffredo P, Ginader T, Thompson D, Hrabe J, Gribovskaja-Rupp I, Kapadia M, Hassan I. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer. J Surg Oncol 2021;123:278-85. [PMID: 33022750 DOI: 10.1002/jso.26244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Goodman K. Total neoadjuvant therapy for rectal cancer. Cancer/Radiothérapie 2018;22:459-65. [DOI: 10.1016/j.canrad.2018.01.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
13 Li N, Wang X, Tang Y, Zhao D, Chi Y, Yang L, Jiang L, Jiang J, Shi J, Liu W, Ren H, Fang H, Tang Y, Chen B, Lu N, Jing H, Qi S, Wang S, Liu Y, Song Y, Li Y, Jin J. Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. Chin J Cancer Res 2021;33:447-56. [PMID: 34584370 DOI: 10.21147/j.issn.1000-9604.2021.04.02] [Reference Citation Analysis]
14 Nout R, Devic S, Niazi T, Wyse J, Boutros M, Pelsser V, Vuong T. CT-based adaptive high-dose-rate endorectal brachytherapy in the preoperative treatment of locally advanced rectal cancer: Technical and practical aspects. Brachytherapy 2016;15:477-84. [DOI: 10.1016/j.brachy.2016.03.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
15 Franke AJ, Skelton WP 4th, George TJ, Iqbal A. A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy. Clin Colorectal Cancer 2021;20:1-19. [PMID: 32863179 DOI: 10.1016/j.clcc.2020.07.009] [Reference Citation Analysis]
16 Bregni G, Akin Telli T, Camera S, Deleporte A, Moretti L, Bali AM, Liberale G, Holbrechts S, Hendlisz A, Sclafani F. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice. Cancer Treat Rev 2020;83:101948. [PMID: 31955069 DOI: 10.1016/j.ctrv.2019.101948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Cho E, Park IJ, Hong SM, Lee JL, Kim CW, Yoon YS, Lim SB, Yu CS, Kim JC. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer. Clin Colorectal Cancer 2019;18:e171-8. [PMID: 31027968 DOI: 10.1016/j.clcc.2019.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W, Jacobs SA, Colangelo LH, Lucas PC, Gollub MJ, Hall WA, Kachnic LA, Vijayvergia N, O'Rourke MA, Faller BA, Valicenti RK, Schefter TE, Moxley KM, Kainthla R, Stella PJ, Sigurdson E, Wolmark N, George TJ. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncol 2021;7:1225-30. [PMID: 34196693 DOI: 10.1001/jamaoncol.2021.1683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li N, Yu J, Luo A, Tang Y, Liu W, Wang S, Liu Y, Song Y, Fang H, Chen B, Qi S, Lu N, Yu Z, Li Y, Liu Z, Jin J. LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. J Cell Biochem 2019;120:5207-17. [PMID: 30320451 DOI: 10.1002/jcb.27796] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Koo K, Ward R, Smith RL, Ruben J, Carne PWG, Elsaleh H. Temporal determinants of tumour response to neoadjuvant rectal radiotherapy. PLoS One 2021;16:e0254018. [PMID: 34191861 DOI: 10.1371/journal.pone.0254018] [Reference Citation Analysis]
21 But-Hadzic J, Boltezar AM, Skerl T, Zadnik V, Velenik V. Preoperative intensity-modulated chemoradiotherapy with simultaneous integrated boost in rectal cancer: five-year follow-up results of a phase II study. Radiol Oncol 2021;55:439-48. [PMID: 34821132 DOI: 10.2478/raon-2021-0028] [Reference Citation Analysis]
22 Shaish H, Aukerman A, Vanguri R, Spinelli A, Armenta P, Jambawalikar S, Makkar J, Bentley-Hibbert S, Del Portillo A, Kiran R, Monti L, Bonifacio C, Kirienko M, Gardner KL, Schwartz L, Keller D. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.Eur Radiol. 2020;30:6263-6273. [PMID: 32500192 DOI: 10.1007/s00330-020-06968-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
23 Bando H, Tsukada Y, Ito M, Yoshino T. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clin Colorectal Cancer 2021:S1533-0028(21)00099-2. [PMID: 34776358 DOI: 10.1016/j.clcc.2021.10.001] [Reference Citation Analysis]
24 Imam I, Hammarström K, Sjöblom T, Glimelius B. Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery? Radiother Oncol 2021;157:70-7. [PMID: 33453311 DOI: 10.1016/j.radonc.2021.01.002] [Reference Citation Analysis]
25 Mukai T, Uehara K, Aiba T, Ogura A, Tsuzuki T, Tanaka A, Sando M, Ohara N, Sato Y, Hattori N, Nakayama G, Kodera Y, Nagino M. Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer. Surg Today 2020;50:912-9. [PMID: 31989238 DOI: 10.1007/s00595-020-01964-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother 2021;26:29-34. [PMID: 33948299 DOI: 10.5603/RPOR.a2021.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Knight KA, Drami I, McMillan DC, Horgan PG, Park JH, Jenkins JT, Roxburgh CSD. Vascular calcification and response to neoadjuvant therapy in locally advanced rectal cancer: an exploratory study. J Cancer Res Clin Oncol 2021. [PMID: 33710416 DOI: 10.1007/s00432-021-03570-1] [Reference Citation Analysis]
28 Sun Y, Zhang Y, Wu X, Lin H, Lu X, Huang Y, Xu Z, Huang S, Wang X, Chi P. Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model. J Surg Oncol. 2018;117:737-744. [PMID: 29228455 DOI: 10.1002/jso.24907] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
29 Lim YJ, Song C, Jeon SH, Kim K, Chie EK. Risk Stratification Using Neoadjuvant Rectal Score in the Era of Neoadjuvant Chemoradiotherapy: Validation With Long-term Outcome Data. Dis Colon Rectum 2021;64:60-70. [PMID: 33306532 DOI: 10.1097/DCR.0000000000001777] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 O'Cathail SM, Wu CH, Thomas R, Hawkins MA, Maughan TS, Lewis A. NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch. Antioxidants (Basel) 2021;10:1380. [PMID: 34573012 DOI: 10.3390/antiox10091380] [Reference Citation Analysis]
31 Chetty R, McCarthy AJ. Neoadjuvant chemoradiation and rectal cancer. J Clin Pathol 2019;72:97-101. [PMID: 30593459 DOI: 10.1136/jclinpath-2018-205592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Chen S, Tang Y, Li N, Jiang J, Jiang L, Chen B, Fang H, Qi S, Hao J, Lu N, Wang S, Song Y, Liu Y, Li Y, Jin J. Development and Validation of an MRI-Based Nomogram Model for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy. Front Oncol 2021;11:784156. [PMID: 34869040 DOI: 10.3389/fonc.2021.784156] [Reference Citation Analysis]
33 Jia AY, Narang A, Safar B, Zaheer A, Murphy A, Azad NS, Gearhart S, Fang S, Efron J, Warczynski T, Hacker-Prietz A, Meyer J. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. Radiat Oncol 2019;14:147. [PMID: 31426827 DOI: 10.1186/s13014-019-1358-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
34 Czito BG, Deming DA, Jameson GS, Mulcahy MF, Vaghefi H, Dudley MW, Holen KD, Deluca A, Mittapalli RK, Munasinghe W, He L, Zalcberg JR, Ngan SY, Komarnitsky P, Michael M. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. The Lancet Gastroenterology & Hepatology 2017;2:418-26. [DOI: 10.1016/s2468-1253(17)30012-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
35 On J, Shim J, Mackay C, Murray G, Samuel L, Parnaby C, Ramsay G. Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival. Colorectal Dis 2021;23:1326-33. [PMID: 33394572 DOI: 10.1111/codi.15512] [Reference Citation Analysis]
36 George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 2019;125:2732-46. [PMID: 31017664 DOI: 10.1002/cncr.32150] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study.J Med Imaging Radiat Oncol. 2020;64:444-449. [PMID: 32386109 DOI: 10.1111/1754-9485.13044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
38 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 2017;8:39-48. [PMID: 28280607 DOI: 10.21037/jgo.2016.11.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
39 El Sissy C, Kirilovsky A, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Galon J, Pagès F. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. Cancers (Basel) 2021;13:1281. [PMID: 33805758 DOI: 10.3390/cancers13061281] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Fu XL, Fang Z, Shu LH, Tao GQ, Wang JQ, Rui ZL, Zhang YJ, Tian ZQ. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Oncotarget 2017;8:34340-51. [PMID: 28423720 DOI: 10.18632/oncotarget.16127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
41 Sun W, Al-Rajabi R, Perez RO, Abbasi S, Ash R, Habr-Gama A. Controversies in Rectal Cancer Treatment and Management. Am Soc Clin Oncol Educ Book 2020;40:1-11. [PMID: 32239978 DOI: 10.1200/EDBK_279871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Chapman WC Jr, Kim H, Bauer P, Makhdoom BA, Trikalinos NA, Pedersen KS, Glasgow SC, Mutch MG, Silviera ML, Roy A, Parikh PJ, Hunt SR. Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy. Dis Colon Rectum 2022;65:198-206. [PMID: 34990423 DOI: 10.1097/DCR.0000000000001997] [Reference Citation Analysis]
43 Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, Kim BG, Lee KW, Kim JW, Oh HS, Ahn JB, Zang DY, Kim DY, Oh JH, Baek JY. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. Int J Radiat Oncol Biol Phys. 2018;101:889-899. [PMID: 29976501 DOI: 10.1016/j.ijrobp.2018.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
44 Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:3212-22. [PMID: 31150315 DOI: 10.1200/JCO.19.00308] [Cited by in Crossref: 105] [Cited by in F6Publishing: 45] [Article Influence: 35.0] [Reference Citation Analysis]
45 Mendis S, To YH, Tie J. Biomarkers in Locally Advanced Rectal Cancer: A Review. Clin Colorectal Cancer 2021:S1533-0028(21)00121-3. [PMID: 34961731 DOI: 10.1016/j.clcc.2021.11.002] [Reference Citation Analysis]
46 Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol 2018;29:1521-7. [PMID: 29718095 DOI: 10.1093/annonc/mdy143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
47 Roselló S, Frasson M, García-Granero E, Roda D, Jordá E, Navarro S, Campos S, Esclápez P, García-Botello S, Flor B, Espí A, Masciocchi C, Valentini V, Cervantes A. Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score. Clin Colorectal Cancer 2018;17:104-112.e2. [PMID: 29162332 DOI: 10.1016/j.clcc.2017.10.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
48 Maeda K, Shibutani M, Tachimori A, Nishii T, Aomatsu N, Fukuoka T, Nagahara H, Otani H, Inoue T, Ohira M. Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy. In Vivo 2020;34:283-9. [PMID: 31882490 DOI: 10.21873/invivo.11772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Roselló S, Cervantes A. Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points. Annals of Oncology 2018;29:1493-4. [DOI: 10.1093/annonc/mdy182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Teo MTW, McParland L, Appelt AL, Sebag-Montefiore D. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. Int J Radiat Oncol Biol Phys 2018;100:146-58. [PMID: 29254769 DOI: 10.1016/j.ijrobp.2017.09.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
51 Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, Murafushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Fujii M, Nakajima T. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial). Radiotherapy and Oncology 2019;134:199-203. [DOI: 10.1016/j.radonc.2019.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 O'Cathail SM, Davis S, Holmes J, Brown R, Fisher K, Seymour L, Adams R, Good J, Sebag-Montefiore D, Maughan T, Hawkins MA. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiat Oncol 2020;15:151. [PMID: 32532291 DOI: 10.1186/s13014-020-01593-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Lim YJ, Kim Y, Kong M. Comparative survival analysis of preoperative and postoperative radiotherapy in stage II-III rectal cancer on the basis of long-term population data. Sci Rep 2018;8:17153. [PMID: 30464308 DOI: 10.1038/s41598-018-35493-2] [Reference Citation Analysis]
54 Huang WS, Kuan FC, Lin MH, Chen MF, Chen WC. Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer. Ann Surg Oncol 2020;27:4309-18. [PMID: 32794029 DOI: 10.1245/s10434-020-09018-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sclafani F, Kalaitzaki E, Cunningham D, Tait D, Brown G, Chau I. Neoadjuvant rectal score: run with the hare and hunt with the hounds. Ann Oncol 2018;29:2261-2. [PMID: 30204839 DOI: 10.1093/annonc/mdy403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
56 Timudom K, Akaraviputh T, Chinswangwatanakul V, Pongpaibul A, Korpraphong P, Petsuksiri J, Ithimakin S, Trakarnsanga A. Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer. World J Gastrointest Surg 2020; 12(9): 390-396 [PMID: 33024513 DOI: 10.4240/wjgs.v12.i9.390] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020;21:e252-64. [PMID: 32359501 DOI: 10.1016/S1470-2045(20)30024-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
58 Delitto D, George TJ Jr, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A. Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. J Natl Cancer Inst 2018;110:460-6. [PMID: 29165692 DOI: 10.1093/jnci/djx228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
59 Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei DR, Cologne KG, Lenz HJ. Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. Oncologist 2020;25:e1879-85. [PMID: 32649004 DOI: 10.1634/theoncologist.2020-0642] [Reference Citation Analysis]
60 Weiser MR, Chou JF, Keshinro A, Chapman WC Jr, Bauer PS, Mutch MG, Parikh PJ, Cercek A, Saltz LB, Gollub MJ, Romesser PB, Crane CH, Shia J, Markowitz AJ, Garcia-Aguilar J, Gönen M; Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. JAMA Netw Open 2021;4:e2133457. [PMID: 34748003 DOI: 10.1001/jamanetworkopen.2021.33457] [Reference Citation Analysis]
61 Sendoya JM, Iseas S, Coraglio M, Golubicki M, Robbio J, Salanova R, Kujaruk M, Mikolaitis V, Rizzolo M, Ruiz G, Cabanne A, Gualdrini U, Mendez G, Hirmas S, Rotondaro C, Viglino J, Eleta M, Fernandez E, Abba M, Podhajcer O, Roca E, Llera AS. Pre-Existing Tumoral B cell Infiltration and Impaired Genome Maintenance Correlate with Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel). 2020;12 . [PMID: 32784964 DOI: 10.3390/cancers12082227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 2017;8:39-48. [PMID: 28280607 DOI: 10.21037/jgo.2016.11.03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 McDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, Kim DW, Lennerz JK, Hazar-Rethinam M, Van Seventer EE, Fetter IJ, Nadres B, Eyler CE, Ryan DP, Weekes CD, Clark JW, Cusack JC, Goyal L, Zhu AX, Wo JY, Blaszkowsky LS, Allen J, Corcoran RB, Hong TS. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250394 DOI: 10.1200/PO.20.00220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Glynne-Jones R, Glynne-Jones S. The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. Lancet Oncol 2021;22:e314-26. [PMID: 34048686 DOI: 10.1016/S1470-2045(21)00053-X] [Reference Citation Analysis]
65 Li N, Jin J, Yu J, Li S, Tang Y, Ren H, Liu W, Wang S, Liu Y, Song Y, Fang H, Yu Z, Li Y. Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus de novo stage pI cohort: A propensity score-matched analysis. Chin J Cancer Res 2018;30:373-81. [PMID: 30046231 DOI: 10.21147/j.issn.1000-9604.2018.03.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]